 Responsiveness patients advanced ovarian carcinoma Gynecologic Oncology Group study second-line therapy patients patients Stage III IV epithelial ovarian cancer disease primary surgery first-line chemotherapy tamoxifen mg response Eighteen percent patients complete response CR partial response PR Thirty-eight percent patients short-term disease stabilization CR median duration months lasting months patients PR stable disease median duration response months maximum duration months estrogen receptors tumor tissue patients CR estrogen receptor levels patients stable progressive disease measurable estrogen receptors